<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03767582</url>
  </required_header>
  <id_info>
    <org_study_id>J18163</org_study_id>
    <secondary_id>IRB00190660</secondary_id>
    <nct_id>NCT03767582</nct_id>
  </id_info>
  <brief_title>Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.</brief_title>
  <official_title>A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual&#xD;
      antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer&#xD;
      (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination&#xD;
      therapy enhances the infiltration of CD8+CD137+ cells in PDACs .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants experiencing study drug-related toxicities</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants who experienced study drug-related toxicities as defined by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants treated with immunotherapy who achieve an immune response</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of participants who have &gt;80% increase of infiltration of CD8+CD137+ T cells into the pancreatic ductal adenocarcinoma after treatment with immunotherapy compared to baseline before treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of months from the time of Cycle 1, Day 1 of immunotherapy until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis free survival (MFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of months from the time of Cycle 1, Day 1 of immunotherapy until first documented distant metastases on imaging per RECIST 1.1 or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local progression free survival (LPFS) Time</measure>
    <time_frame>3 years</time_frame>
    <description>Number of months from the time of Cycle 1, Day 1 of immunotherapy until first documented local progression or relapse from complete response on imaging (using RECIST 1.1 criteria and irRECIST criteria) or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Resectability Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants who are able to undergo successful tumor resection (as defined by R0 and R1 resection).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological Response Rate</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants who have a pathologic complete response as determined by surgical margins and residual disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life score based on EORTC QLQ-C30/Pan26</measure>
    <time_frame>Baseline, 3 years</time_frame>
    <description>Change in quality of life from baseline will be evaluated using the European Organization for Research and Treatment of Cancer core questionnaire, pancreatic cancer module (EORTC QLQ-C30/Pan26). The QLQ-C30 includes 30 questions assessing global health status/quality of life, function, and symptoms. The PAN26 module comprises of an additional 26 questions assessing pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes). The score for each item ranges from 0-100, with a higher score reflecting a better level of functioning, a better quality of life, or a worse level of symptoms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation (SBRT)</intervention_name>
    <description>SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)</description>
    <arm_group_label>Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_label>Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_label>Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.</description>
    <arm_group_label>Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_label>Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_label>Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCR2/CCR5 dual antagonist</intervention_name>
    <description>CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.</description>
    <arm_group_label>Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_label>Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_label>Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist</arm_group_label>
    <other_name>BMS-813160</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GVAX</intervention_name>
    <description>Vaccine (5x10^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.</description>
    <arm_group_label>Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist</arm_group_label>
    <arm_group_label>Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist</arm_group_label>
    <other_name>PANC 10.05 pcDNA-1/GM-Neo vaccine</other_name>
    <other_name>PANC 6.03 pcDNA-1/GM-Neo vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  Patients with histologically- or cytologically-proven, surgically unresectable,&#xD;
             locally advanced pancreatic adenocarcinoma.&#xD;
&#xD;
          -  If the patient does not have a diagnostic biopsy that is adequate for review at our&#xD;
             institution, the patient must agree to a research core biopsy to be performed at Johns&#xD;
             Hopkins.&#xD;
&#xD;
          -  If the patient's available imaging is not adequate for review by our institution, the&#xD;
             patient must agree to a repeat imaging to be performed at Johns Hopkins.&#xD;
&#xD;
          -  Patients cannot have had any prior therapy for the locally advanced pancreatic&#xD;
             adenocarcinoma.&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy greater than 3 months.&#xD;
&#xD;
          -  Able to swallow pills or capsules.&#xD;
&#xD;
          -  Patient must have adequate organ function defined by the study-specified laboratory&#xD;
             tests.&#xD;
&#xD;
          -  Patients must be eligible to receive FOLFIRINOX-based chemotherapy.&#xD;
&#xD;
          -  Patients must be willing to be treated with stereotactic body radiation therapy (SBRT)&#xD;
             only at Johns Hopkins Hospital.&#xD;
&#xD;
          -  Patients must be willing to undergo a core biopsy of the pancreatic cancer.&#xD;
&#xD;
          -  Patients must be willing to undergo a biopsy of the pancreatic cancer if the patient&#xD;
             is not deemed a surgical candidate during the pre-surgical evaluation.&#xD;
&#xD;
          -  Must use acceptable form of birth control while on study.&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have had non-FOLFIRINOX-based chemotherapy for the pancreatic cancer.&#xD;
&#xD;
          -  Have received any anti-neoplastic biologics, vaccines or hormonal treatment, including&#xD;
             investigational drugs, within 28 days of the first dose of study.&#xD;
&#xD;
          -  History of past treatment with immunotherapy agents prior to initial enrollment into&#xD;
             this study (including, but not limited to: IL-2, interferon, anti-PD-1, anti-PD-L1,&#xD;
             anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, anti-CTLA-4 or anti-CCR2/5 drugs).&#xD;
&#xD;
          -  Have had prior organ or tissue allograft or allogeneic bone marrow transplantation,&#xD;
             including corneal transplants.&#xD;
&#xD;
          -  Is currently participating or has participated in a study of an investigational agent&#xD;
             or using an investigational device for the treatment of cancer.&#xD;
&#xD;
          -  Current use of immunosuppressive medications within 14 days prior to study&#xD;
             medications.&#xD;
&#xD;
          -  Have received any vaccine within 14 days prior to study medications.&#xD;
&#xD;
          -  Receiving growth factors including, but not limited to, granulocyte-colony stimulating&#xD;
             factor (G-CSF), GM-CSF, erythropoietin, within 14 days of the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  History of any autoimmune disease. Patients with thyroid disease will be allowed.&#xD;
&#xD;
          -  Has a history of (non-infectious) pneumonitis or current pneumonitis.&#xD;
&#xD;
          -  Has a pulse oximetry &lt; 92% on room air.&#xD;
&#xD;
          -  Requires the use of home oxygen.&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness including, but not limited to,&#xD;
             myocardial infarction or stroke/transient ischemic attack within the past 6 months,&#xD;
             uncontrolled infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  12-lead electrocardiogram with QRS ≥ 120 msec, except right bundle branch block ; QTcF&#xD;
             (QT corrected for heart rate using Fridericia's method) ≥ 480 msec, except right&#xD;
             bundle branch block&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Infection with HIV or hepatitis B or C.&#xD;
&#xD;
          -  Any concurrent malignancy other than non-melanoma skin cancer, non-invasive bladder&#xD;
             cancer, early stage prostate cancer, or carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Current or recent (within 3 months of study treatment administration) gastrointestinal&#xD;
             disease that could impact the absorption of study treatment.&#xD;
&#xD;
          -  Any gastrointestinal surgery that is likely impact upon the absorption of study&#xD;
             treatment.&#xD;
&#xD;
          -  Inability to tolerate oral medication.&#xD;
&#xD;
          -  Unable to have blood drawn.&#xD;
&#xD;
          -  Have had surgery within 28 days of the first dose of study medication.&#xD;
&#xD;
          -  Prior use of strong/moderate CYP3A4 inhibitors or inducers within 28 days of the first&#xD;
             dose of BMS-813160.&#xD;
&#xD;
          -  Prior use of Class I antiarrhythmics within 28 days of first dose of study medication.&#xD;
&#xD;
          -  Has ascites requiring medical management.&#xD;
&#xD;
          -  Presence of duodenal or gastric invasion by the tumor.&#xD;
&#xD;
          -  Hypersensitivity reaction to any monoclonal antibody.&#xD;
&#xD;
          -  Known allergy or hypersensitivity to study drugs or any of their components of the&#xD;
             study arm that participant is enrolling.&#xD;
&#xD;
          -  Woman who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Patient is unwilling or unable to follow the study schedule for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Zheng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen Apostal, RN</last_name>
    <phone>410-614-3644</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joann Santmyer</last_name>
    <phone>410-614-3644</phone>
    <email>GIClinicalTrials@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Brothers, RN</last_name>
      <phone>410-614-3644</phone>
      <email>GIClinicalTrials@jhmi.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2023</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>September 1, 2023</last_update_submitted>
  <last_update_submitted_qc>September 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GVAX</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>CCR2/CCR5 dual antagonist</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Cancer vaccine</keyword>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>Myeloid modulating agent</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Stereotactic body radiation therapy</keyword>
  <keyword>SBRT</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Pancreatic Ductal Adenocarcinoma</keyword>
  <keyword>PDAC</keyword>
  <keyword>Locally advanced pancreatic ductal adenocarcinoma</keyword>
  <keyword>LAPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03767582
org study id: J18163
secondary id: IRB00190660
nct id: NCT03767582
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual
      antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer
      (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination
      therapy enhances the infiltration of CD8+CD137+ cells in PDACs .
allocation: Randomized
intervention model: Sequential Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Number of Participants experiencing study drug-related toxicities
time frame: 3 years
description: Number of participants who experienced study drug-related toxicities as defined by CTCAE v5.0
measure: Percentage of participants treated with immunotherapy who achieve an immune response
time frame: 3 years
description: Percentage of participants who have >80% increase of infiltration of CD8+CD137+ T cells into the pancreatic ductal adenocarcinoma after treatment with immunotherapy compared to baseline before treatment.
measure: Overall survival (OS)
time frame: 3 years
description: Number of months from the time of Cycle 1, Day 1 of immunotherapy until death from any cause
measure: Metastasis free survival (MFS)
time frame: 3 years
description: Number of months from the time of Cycle 1, Day 1 of immunotherapy until first documented distant metastases on imaging per RECIST 1.1 or death from any cause, whichever occurs first.
measure: Local progression free survival (LPFS) Time
time frame: 3 years
description: Number of months from the time of Cycle 1, Day 1 of immunotherapy until first documented local progression or relapse from complete response on imaging (using RECIST 1.1 criteria and irRECIST criteria) or death from any cause, whichever occurs first.
measure: Surgical Resectability Rate
time frame: 3 years
description: Number of participants who are able to undergo successful tumor resection (as defined by R0 and R1 resection).
measure: Pathological Response Rate
time frame: 3 years
description: Number of participants who have a pathologic complete response as determined by surgical margins and residual disease.
measure: Change in Quality of life score based on EORTC QLQ-C30/Pan26
time frame: Baseline, 3 years
description: Change in quality of life from baseline will be evaluated using the European Organization for Research and Treatment of Cancer core questionnaire, pancreatic cancer module (EORTC QLQ-C30/Pan26). The QLQ-C30 includes 30 questions assessing global health status/quality of life, function, and symptoms. The PAN26 module comprises of an additional 26 questions assessing pain, dietary changes, jaundice, altered bowel habit, emotional problems related to pancreatic cancer, and other symptoms (cachexia, indigestion, flatulence, dry mouth, taste changes). The score for each item ranges from 0-100, with a higher score reflecting a better level of functioning, a better quality of life, or a worse level of symptoms.
arm group label: Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist
arm group type: Experimental
arm group label: Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist
arm group type: Experimental
arm group label: Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist
arm group type: Experimental
intervention type: Radiation
intervention name: Stereotactic Body Radiation (SBRT)
description: SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
arm group label: Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist
arm group label: Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist
arm group label: Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist
intervention type: Drug
intervention name: Nivolumab
description: Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
arm group label: Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist
arm group label: Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist
arm group label: Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist
other name: OPDIVO
intervention type: Drug
intervention name: CCR2/CCR5 dual antagonist
description: CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
arm group label: Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist
arm group label: Phase II - Arm A: Nivolumab/CCR2/CCR5 dual antagonist
arm group label: Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist
other name: BMS-813160
intervention type: Drug
intervention name: GVAX
description: Vaccine (5x10^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
arm group label: Phase I - GVAX/Nivolumab/CCR2/CCR5 dual antagonist
arm group label: Phase II - Arm B: Nivolumab/GVAX/CCR2/CCR5 dual antagonist
other name: PANC 10.05 pcDNA-1/GM-Neo vaccine
other name: PANC 6.03 pcDNA-1/GM-Neo vaccine
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Lei Zheng, MD
role: Principal Investigator
affiliation: Johns Hopkins Medical Institution
last name: Colleen Apostal, RN
phone: 410-614-3644
email: GIClinicalTrials@jhmi.edu
last name: Joann Santmyer
phone: 410-614-3644
email: GIClinicalTrials@jhmi.edu
facility: 
status: Recruiting
contact: 
country: United States
responsible party type: Sponsor
mesh term: Adenocarcinoma
mesh term: Nivolumab
mesh term: Vaccines
sharing ipd: Undecided